Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

Seul-Gee Lee(Yonsei University), Jung‐Sun Kim(Yonsei University)

BMC Medicine

September 7, 2022

10.1186/s12916-022-02485-z

Cited by 63

Related Papers

A New Strategy for Discontinuation of Dual Antiplatelet Therapy

|Journal of the American College of Cardiology|2012|643

Effect of Intravascular Ultrasound–Guided vs Angiography-Guided Everolimus-Eluting Stent Implantation

|JAMA|2015|603

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome

|JAMA|2020|548

Optical coherence tomography in coronary atherosclerosis assessment and intervention

|Nature Reviews Cardiology|2022|397

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

|The Lancet|2022|304